AI can identify genetic perturbations from cell images, offering new path for drug discovery. Story by Werner Siefer • 1mo.

They’re using simple methods, she said, but in a field where things are so new and moving so fast, it’s still pushing the envelope of biology and drug discovery.

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

Sensors don’t have to be electronic things; chemists are working hard on clever systems that use phase chemistry to tip off ...

BostonGene, a leader in AI-powered solutions for drug discovery and development, is transforming how pharmaceutical companies develop, target, and deliver cancer therapies — making precision ...

And drug discovery is a prime focus for many of the highest valued AI companies working in pharma. Tempus AI, which has a market cap of about $9 billion, got its start leveraging molecular data ...

Her research group develops algorithms and strategies for large-scale experiments involving images. The team’s open-source CellProfiler software is used by thousands of biologists worldwide and their ...

Taiwan’s biotech industry is living its golden days, and LumiSTAR is certainly one of its shining examples. It all started at Oxford University, when LumiSTAR co-founders Yu-Fen Chang, CEO, and ...

Isomorphic Labs, a Google DeepMind spin-off focused on drug discovery, more than quadrupled its research and development spend for 2023. ... Toby Melville/POOL/AFP via Getty Images.